|
gptkbp:instanceOf
|
gptkb:person
|
|
gptkbp:almaMater
|
gptkb:University_of_North_Carolina_at_Chapel_Hill
|
|
gptkbp:birthYear
|
1966
|
|
gptkbp:employer
|
gptkb:University_of_North_Carolina_School_of_Medicine
|
|
gptkbp:fieldOfWork
|
oncology
cancer biology
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Norman E. Sharpless
|
|
gptkbp:memberOf
|
gptkb:American_Society_for_Clinical_Investigation
gptkb:Association_of_American_Physicians
|
|
gptkbp:nationality
|
gptkb:American
|
|
gptkbp:notableWork
|
research on cell aging and cancer
|
|
gptkbp:occupation
|
gptkb:cancer
gptkb:physician
oncologist
|
|
gptkbp:positionHeld
|
Director of the National Cancer Institute
Acting Commissioner of the U.S. Food and Drug Administration
|
|
gptkbp:predecessor_(Acting_FDA_Commissioner)
|
gptkb:Scott_Gottlieb
|
|
gptkbp:predecessor_(NCI_Director)
|
gptkb:Douglas_Lowy
|
|
gptkbp:successor_(Acting_FDA_Commissioner)
|
gptkb:Stephen_Hahn
|
|
gptkbp:successor_(NCI_Director)
|
gptkb:Douglas_Lowy
|
|
gptkbp:termEnd_(Acting_FDA_Commissioner)
|
November 2019
|
|
gptkbp:termEnd_(NCI_Director)
|
April 2022
|
|
gptkbp:termStart_(Acting_FDA_Commissioner)
|
April 2019
|
|
gptkbp:termStart_(NCI_Director)
|
October 2017
|
|
gptkbp:bfsParent
|
gptkb:G1_Therapeutics
|
|
gptkbp:bfsLayer
|
7
|